597563-44-5Relevant academic research and scientific papers
BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS
-
Paragraph 0473-0474; 0503-0504, (2021/11/13)
The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
UREA DERIVATIVES USEFUL AS KINASE INHIBITORS
-
Page/Page column 165, (2015/07/07)
There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
